- Home
- AAM vs FTRE Comparison
AAM vs FTRE Comparison
Compare AAM & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AAM
- FTRE
- Stock Information
- Founded
- AAM 2024
- FTRE 1996
- Country
- AAM United States
- FTRE United States
- Employees
- AAM N/A
- FTRE N/A
- Industry
- AAM
- FTRE Medical Specialities
- Sector
- AAM
- FTRE Health Care
- Exchange
- AAM Nasdaq
- FTRE Nasdaq
- Market Cap
- AAM 458.2M
- FTRE 469.0M
- IPO Year
- AAM 2024
- FTRE N/A
- Fundamental
- Price
- AAM $10.44
- FTRE $4.95
- Analyst Decision
- AAM
- FTRE Hold
- Analyst Count
- AAM 0
- FTRE 11
- Target Price
- AAM N/A
- FTRE $17.10
- AVG Volume (30 Days)
- AAM 18.8K
- FTRE 3.0M
- Earning Date
- AAM 01-01-0001
- FTRE 08-11-2025
- Dividend Yield
- AAM N/A
- FTRE N/A
- EPS Growth
- AAM N/A
- FTRE N/A
- EPS
- AAM 0.30
- FTRE N/A
- Revenue
- AAM N/A
- FTRE $2,685,600,000.00
- Revenue This Year
- AAM N/A
- FTRE N/A
- Revenue Next Year
- AAM N/A
- FTRE $1.36
- P/E Ratio
- AAM $34.87
- FTRE N/A
- Revenue Growth
- AAM N/A
- FTRE N/A
- 52 Week Low
- AAM $9.96
- FTRE $3.97
- 52 Week High
- AAM $10.79
- FTRE $28.41
- Technical
- Relative Strength Index (RSI)
- AAM N/A
- FTRE 43.05
- Support Level
- AAM N/A
- FTRE $5.11
- Resistance Level
- AAM N/A
- FTRE $5.46
- Average True Range (ATR)
- AAM 0.00
- FTRE 0.40
- MACD
- AAM 0.00
- FTRE -0.04
- Stochastic Oscillator
- AAM 0.00
- FTRE 0.00
About AAM AA Mission Acquisition Corp. Class A Ordinary Shares
AA Mission Acquisition Corp is a blank check company.
About FTRE Fortrea Holdings Inc.
Fortrea Holdings is a late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.